Broad-spectrum targeted next-generation sequencing: is it ready for routine deployment in intensive care units for severe pneumonia? - Takeaways - MDSpire

Broad-spectrum targeted next-generation sequencing: is it ready for routine deployment in intensive care units for severe pneumonia?

  • By

  • How-Yang Tseng

  • Yu-Chang Fu

  • Yue-Hua Su

  • Yu-Chu Kuo

  • Shinn-Jye Liang

  • Yi-Cheng Shen

  • Wei-Cheng Chen

  • Chieh-Lung Chen

  • Yu-Chao Lin

  • Meng-Yu Cheng

  • Chih-Hao Chen

  • Chih-Yen Tu

  • Zi-Lun Lai

  • Po-Ren Hsueh

  • April 2, 2026

  • 0 min

Share

  • 1

    Targeted next-generation sequencing (tNGS) shows a higher diagnostic yield than conventional microbiological tests for respiratory pathogens.

  • 2

    In a study of 51 ICU patients, tNGS had a detection rate of 90.2%, compared to 82.4% for standard testing methods.

  • 3

    Despite its advantages, tNGS faces challenges in routine ICU implementation, including optimal timing and cost considerations.

  • 4

    Non-infectious conditions mimicking pneumonia complicate diagnosis, with 45.1% of cases remaining without an identified pathogen.

  • 5

    Successful clinical implementation of tNGS requires managing laboratory workflows, turnaround times, and bioinformatic interpretation.

Original Source(s)

Broad-spectrum targeted next-generation sequencing: is it ready for routine deployment in intensive care units for severe pneumonia?

  • by How-Yang Tseng, Yu-Chang Fu, Yue-Hua Su, Yu-Chu Kuo, Shinn-Jye Liang, Yi-Cheng Shen, Wei-Cheng Chen, Chieh-Lung Chen, Yu-Chao Lin, Meng-Yu Cheng, Chih-Hao Chen, Chih-Yen Tu, Zi-Lun Lai, Po-Ren Hsueh

  • April 2, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Staphylococcus aureus small colony variants originating from the lower respiratory tract are associated with persistent pulmonary infection

Association of Systemic Inflammatory Markers with 28-Day Mortality in Patients with Severe Pneumonia: A Retrospective Study from a Single Center